FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024
SHELTON, Conn., Jan. 3, 2024.
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a.
/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.
/PRNewswire/ AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was.